Diabetes, Diabetes Mellitus, Type 1
Conditions
Brief summary
This trial is conducted in Europe. The aim of the trial is to investigate the postprandial glucose metabolism after treatment with faster-acting insulin aspart in subjects with type 1 diabetes.
Interventions
DRUGFaster-acting insulin aspart
Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
DRUGinsulin aspart
Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* Male or female aged 18-64 years (both inclusive) at the time of signing informed consent * Subjects diagnosed (clinically) with type 1 diabetes mellitus at least 365 days prior to the day of screening * Body mass index 18.5-28.0 kg/m\^2 (both inclusive)
Exclusion criteria
* Smoker (defined as a subject who is smoking at least five cigarettes or the equivalent per day) who is not able or willing to refrain from smoking or use of nicotine gum or transdermal nicotine patches during the inpatient period * Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in plasma glucose concentration | From 0-1 hour after trial product administration |
Secondary
| Measure | Time frame |
|---|---|
| Rate of endogenous glucose production | From 0-6 hours after trial product administration |
| Area under the serum insulin aspart concentration-time curve | From 0-6 hours after trial product administration |
Countries
Austria
Outcome results
None listed